Alexza Pharmaceuticals to Present AZ-001 Phase IIb Clinical Data at the American Headache Society Meeting
Posted on: Thursday, 31 May 2007, 09:00 CDT
PALO ALTO, Calif., May 31 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. announced today that it will present at the 49th Annual American Headache Society Meeting the results of a Phase IIb clinical trial of Staccato(R) prochlorperazine (AZ-001) for the acute treatment of migraine headache. The poster presentation, "Efficacy and tolerability profile of AZ-001 (Staccato prochlorperazine) in patients with migraine headache" (Poster S-72), will be available for viewing at the meeting at the Hyatt Regency Chicago Hotel in Chicago, Illinois on Saturday, June 9, 2007 from 12:15 to 1:00 pm.
Alexza Pharmaceuticals is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. The Company has five product candidates in clinical development; AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-003 (Staccato fentanyl) for the treatment of patients with acute pain and AZ-007 (Staccato zaleplon) for the treatment of sleep disorder in patients who have difficulty falling asleep.
Alexza Pharmaceuticals, Inc.
CONTACT: Thomas B. King, President & CEO of Alexza Pharmaceuticals,Inc., +1-650-687-3900, tking@alexza.com
Web site: http://www.alexza.com/
Source: PRNewswire-FirstCall
Related Articles
- Many Heart Failure Patients Do Not Get Proper Drug Treatments
- Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
- Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
- Noven Announces Final FDA Approval of Stavzor(TM) for the Treatment of Bipolar Disorder, Seizures and Migraine Headaches
- Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients With Migraine Headache
- Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
- Seventy-Eight Percent of Newly Diagnosed Dyslipidemia Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- Alexza Completes Enrollment in AZ-001 Phase IIb Clinical Trial in Patients With Migraine Headaches
- Alexza Initiates AZ-001 Phase IIb Clinical Trial in Patients With Migraine Headaches
 |
 |
User Comments (0)
RSS Feeds